ReviewProgress in cardiovascular diseases
Asymptomatic peripheral artery disease: Silent but deadly.
Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Association between novel hematological inflammatory indices and prevalent peripheral arterial disease: A cross-sectional analysis from the national health and nutrition examination survey.Science progress · 2026Article
- Alternative ankle-brachial assessments show no significant added value in predicting mortality of hypertensive patients.Journal of hypertension · 2026Article
- Femoral Plaque Burden and Left Ventricular-Arterial Coupling in Patients with Chronic Heart Failure.Journal of clinical medicine · 2026Article
- The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: a prospective cohort study.Frontiers in endocrinology · 2026Article
- The Pulse of Progress: James S.T. Yao, MD, PhD's Breakthrough Ankle-Brachial Index and Biography.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Observational
- Prognostic Significance of Peripheral Artery Disease in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2023Article
- Assessing Automatic Plethysmographic Ankle-Brachial Index Devices in Peripheral Artery Disease Detection: A Comparative Study with Doppler Ankle-Brachial Index Measurements.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease.European journal of medical research · 2023Review
- Therapeutic angiogenesis-based strategy for peripheral artery disease.Theranostics · 2022Review
- A rare case of sigmoid colon cancer in which the lower limbs received collateral blood flow from the inferior mesenteric artery owing to peripheral artery disease.Surgical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Peripheral Artery Disease (PAD) is a manifestation of atherosclerosis characterized by diminished perfusion of the limb and a state of dysmetabolism. The asymptomatic PAD phenotype is a relatively recent classification. It is unknown how many people currently live with asymptomatic PAD because there are no universal screening recommendations for patients at risk for PAD. Patients with asymptomatic PAD suffer from a similar risk profile of morbidity and mortality as their counterparts with claudication. Despite this increased risk, there is a dearth of clinical investigations into therapies that specifically benefit the asymptomatic PAD population. At present, current pharmacotherapies that have been studied in PAD patient populations do not stratify by symptom status. We believe that further investigation of the impact of existing therapies in this unique population presents an opportunity to reduce morbidity and mortality due to PAD. This can only be achieved in combination with wide-spread adoption of screening for asymptomatic PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.